Lata Maganti
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Pharmaceutical studies and practices, Antibiotics Pharmacokinetics and Efficacy, Statistical Methods in Clinical Trials, Bone health and treatments, Respiratory viral infections research
Most-Cited Works
- → Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy(2009)84 cited
- → Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies(2008)42 cited
- → Pharmacokinetics and Safety of Montelukast Oral Granules in Children 1 to 3 Months of Age With Bronchiolitis(2008)28 cited
- → Pharmacokinetics and Safety of Montelukast in Children Aged 3 to 6 Months(2006)28 cited
- → Bioavailability of Alendronate and Vitamin D3in an Alendronate/Vitamin D3Combination Tablet(2010)21 cited
- → A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes(2018)16 cited
- → In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections(2016)5 cited
- → Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial(2024)5 cited
- → Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery(2020)3 cited
- → Pooled analysis of routine safety parameters observed in healthy participants at baseline and following placebo administration in early phase clinical studies(2024)2 cited